

Gi-Ae Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4790216/publications.pdf>

Version: 2024-02-01

28
papers

1,495
citations

516710

16
h-index

642732

23
g-index

28
all docs

28
docs citations

28
times ranked

2047
citing authors

#	ARTICLE	IF	CITATIONS
1	Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	17
2	Association between non-alcoholic fatty liver disease and the risk of dementia: A nationwide cohort study. <i>Liver International</i> , 2022, 42, 1027-1036.	3.9	23
3	Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B. <i>Gut</i> , 2021, 70, 2172-2182.	12.1	30
4	Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 763-763.	3.7	0
5	Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2020, 115, 406-414.	0.4	29
6	Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 576-577.	3.7	1
7	Reduced liver cancer mortality with regular clinic follow-up among patients with chronic hepatitis B: A nationwide cohort study. <i>Cancer Medicine</i> , 2020, 9, 7781-7791.	2.8	6
8	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222.	12.1	20
9	Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1169-1179.	3.7	50
10	Editorial: hepatitis B DNA thresholds and risk of hepatocellular carcinoma: different number patterns in HBeAg-positive versus HBeAg-negative patients. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1440-1441.	3.7	1
11	High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 215-226.	3.7	68
12	Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-stage Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 1983-1994.	7.3	127
13	Effect of Statin Use on Liver Cancer Mortality Considering Hypercholesterolemia and Obesity in Patients with Non-Cirrhotic Chronic Hepatitis B. <i>Yonsei Medical Journal</i> , 2019, 60, 1203.	2.2	10
14	Age-Related Decrease in Skeletal Muscle Mass Is an Independent Risk Factor for Incident Nonalcoholic Fatty Liver Disease: A 10-Year Retrospective Cohort Study. <i>Gut and Liver</i> , 2019, 13, 67-76.	2.9	57
15	Reply to: "The role of NAFLD in extrahepatic malignancies: The importance of ruling out the effect of obesity". <i>Journal of Hepatology</i> , 2018, 68, 1094-1095.	3.7	1
16	Response to: "Prognosis of immune-tolerant phase chronic hepatitis B" by Chu and Liaw. <i>Gut</i> , 2018, 67, 988.2-989.	12.1	0
17	High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. <i>Gut</i> , 2018, 67, 945-952.	12.1	176
18	Association between non-alcoholic fatty liver disease and cancer incidence rate. <i>Journal of Hepatology</i> , 2018, 68, 140-146.	3.7	185

#	ARTICLE	IF	CITATIONS
19	IDDF2018-ABS-0200â€¦Non-linear association between serum hepatitis B virus dna levels and hepatocellular carcinoma risk in treatment-naive, non-cirrhotic chronic hepatitis B patients. , 2018, , .		0
20	IDDF2018-ABS-0150â€¦Risk of hepatocellular cancer and death/transplant between inactive hepatitis b and hbeag-negative chronic hepatitis b with antiviral agents. , 2018, , .		0
21	Chronic Hepatitis B Infection Is Significantly Associated with Chronic Kidney Disease: a Population-based, Matched Case-control Study. Journal of Korean Medical Science, 2018, 33, e264.	2.5	13
22	Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial. BMC Gastroenterology, 2017, 17, 15.	2.0	11
23	Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization. Journal of Hepatology, 2015, 62, 1076-1084.	3.7	21
24	Comparison of Chemoembolization with and without Radiation Therapy and Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis. Journal of Vascular and Interventional Radiology, 2015, 26, 320-329.e6.	0.5	75
25	Reappraisal of serum alphaâ€œfetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. Liver International, 2015, 35, 232-239.	3.9	35
26	Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: A need for surveillance. Journal of Hepatology, 2015, 62, 1092-1099.	3.7	114
27	Evaluation of Early-Stage Hepatocellular Carcinoma by Magnetic Resonance Imaging With Gadoxetic Acid Detects Additional Lesions and Increases Overall Survival. Gastroenterology, 2015, 148, 1371-1382.	1.3	106
28	HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut, 2014, 63, 1325-1332.	12.1	319